An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

B, Damholt; G, Golor; W, Wierich; P, Pedersen; M, Ekblom; M, Zdravkovic

doi:10.1177/0091270006288215

Public

An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

Shared by NobleBlocks on Jun 1, 2006 • 12:00 AM UTC

Authors:

Damholt B

Golor G

Wierich W

Abstract

Liraglutide is a once-daily glucagon-like peptide-1 analogue being developed for the treatment of type 2 diabetes. The aim of this study was to investigate the effect of age and gender on the pharmacokinetics of liraglutide. Eight male and 8 female subjects were recruited from an 18- to 45-year-old ...

Discussions